United States:
Despite Granting A Request For Rehearing, The PTAB Maintained Its Finding That Teva's Copaxone Claims Were Unpatentable As Obvious, PTAB Litigation Blog
30 December 2016
Jones Day
To print this article, all you need is to be registered or login on Mondaq.com.
In Mylan Pharmaceuticals Inc. and Amneal Pharmaceuticals LLC
v. Yeda Research & Development Co. Ltd., IPR2015-00643; -00644; -00830, the PTAB
granted-in-part Patent Owner Teva's request for rehearing of
the Final Written Decisions finding every claim of the challenged
patents obvious over the prior art. In granting rehearing in
part, the PTAB vacated its original decisions and concurrently
entered modified Final Written Decisions maintaining that the
challenged claims are unpatentable as obvious over the prior
art.
Read the full article at
ptablitigationblog.com.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Are Your NDAs Up To Date?
Wolf, Greenfield & Sacks, P.C.
Nondisclosure agreements (NDAs) can be used to protect companies' confi dential and trade secret information. But you should resist the urge to have a vendor...
Legal Implications Of New York Times vs. OpenAI
BoyarMiller
The New York Times recently filed a landmark lawsuit against OpenAI and Microsoft, accusing them of copyright infringement in the training of the chatbot ChatGPT which launched just over a year ago.
